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Pngiotensin II Receptor Blockade Reduces
ew-Onset Atrial Fibrillation and
ubsequent Stroke Compared to Atenolol
he Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study
ristian Wachtell, MD, PHD,*† Mika Lehto, MD,‡ Eva Gerdts, MD, PHD,§
ichael H. Olsen, MD, PHD,* Björn Hornestam, MD, Björn Dahlöf, MD, PHD, FACC,
ans Ibsen, MD,* Stevo Julius, MD, FACC,¶ Sverre E. Kjeldsen, MD, PHD, FACC,¶#
ars H. Lindholm, MD, FACC,** Markku S. Nieminen, MD, FACC,‡ Richard B. Devereux, MD, FACC†
lostrup, Denmark; New York, New York; Helsinki, Finland; Bergen and Oslo, Norway; Gothenburg and Umeå,
weden; and Ann Arbor, Michigan
OBJECTIVES This study was designed to evaluate whether different antihypertensive treatment regimens
with similar blood pressure reduction have different effects on new-onset atrial fibrillation
(AF).
BACKGROUND It is unknown whether angiotensin II receptor blockade is better than beta-blockade in
preventing new-onset AF.
METHODS In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193
hypertensive patients and patients with electrocardiogram-documented left ventricular
hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive
therapy. Electrocardiograms were Minnesota coded centrally, and 8,851 patients without AF
by electrocardiogram or history, who were thus at risk of developing AF, were followed for
4.8  1.0 years.
RESULTS New-onset AF occurred in 150 patients randomized to losartan versus 221 to atenolol (6.8 vs.
10.1 per 1,000 person-years; relative risk 0.67, 95% confidence interval [CI] 0.55 to 0.83, p
 0.001) despite similar blood pressure reduction. Patients receiving losartan tended to stay
in sinus rhythm longer (1,809  225 vs. 1,709  254 days from baseline, p  0.057) than
those receiving atenolol. Moreover, patients with new-onset AF had two-, three- and fivefold
increased rates, respectively, of cardiovascular events, stroke, and hospitalization for heart
failure. There were fewer composite end points (n  31 vs. 51, hazard ratio  0.60, 95% CI
0.38 to 0.94, p  0.03) and strokes (n  19 vs. 38, hazard ratio  0.49, 95% CI 0.29 to 0.86,
p  0.01) in patients who developed new-onset AF in the losartan compared to the atenolol
treatment arm of the study. Furthermore, Cox regression analysis showed that losartan (21%
risk reduction) and new-onset AF both independently predicted stroke even when adjusting
for traditional risk factors.
CONCLUSIONS Our novel finding is that new-onset AF and associated stroke were significantly reduced by
losartan- compared to atenolol-based antihypertensive treatment with similar blood pressure
reduction. (J Am Coll Cardiol 2005;45:712–9) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.068Cardiology Foundation
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atrial fibrillation (AF) is associated with increased cardio-
ascular risk, and the incidence of AF is increased in
atients with uncontrolled hypertension (1–3). Antihyper-
ensive treatment reduces new-onset AF. However, it is
nclear whether there is difference in risk of new-onset AF
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004, accepted October 26, 2004.ith different antihypertensive drugs. To our knowledge
nly one study in post-infarct patients suggests that renin-
ngiotensin system blockade, compared to placebo, reduces
See page 720
ew-onset AF and helps maintain sinus rhythm (4). As this
as a placebo-controlled study, it is not known whether this
utcome was a result of blood pressure reduction per se or a
irect effect of renin-angiotensin system blockade. Several
nimal and human studies suggest antiarrhythmic properties
f renin-angiotensin blockade, but none address whether
he beneficial effect is independent of potential blood
ressure reduction by angiotensin-converting enzyme inhib-
tors/angiotensin II receptor blockers (5–9). Furthermore,
lthough AF is a frequent complication of hypertension,
here is little evidence that choosing what many regard as
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March 1, 2005:712–9 AF in Hypertensive Patientsrst-line therapy, beta-blockade with combined antiar-
hythmic and antihypertensive properties, is better than
ther antihypertensive treatments in preventing AF (10).
ne striking result of the Losartan Intervention For End-
oint reduction in hypertension (LIFE) study was a 25%
eduction of fatal and nonfatal stroke by losartan-based
reatment. This result was in part explained by a 45% lower
ate of stroke (24.1 vs. 46.5 strokes per 1,000 patient-years
f follow-up) on losartan treatment in patients with a
istory of AF (11), but could also reflect benefits of reduced
ew-onset AF.
The present study was undertaken to determine whether
elective angiotensin II type 1 receptor blockade with
osartan was more effective than beta-blockade with atenolol
n reducing new-onset AF and associated cardiovascular
vents in hypertensive patients with electrocardiographic
ECG) left ventricular (LV) hypertrophy.
ETHODS
he LIFE study was a prospective, randomized, double-
asked, parallel group study (n  9,193) with double-
ummy technique that evaluated the long-term effects of
osartan- compared to atenolol-based antihypertensive ther-
py in patients with hypertension and ECG LV hypertro-
hy on cardiovascular morbidity and mortality. The main
utcome (12) and the complete study protocol with study
esign, organization, clinical measures, exclusion criteria,
asis for choice of comparative agents, statistical consider-
tions, and baseline characteristics (13,14) have been pub-
ished. We have reported a lower rate of cardiovascular
vents with losartan- compared to atenolol-based treatment
n 342 LIFE patients with AF before or at study baseline
11). The remaining 8,851 patients with ECG-documented
inus rhythm at baseline and no history of AF who were at
isk of developing AF during the study are the focus of this
tudy (Fig. 1).
As previously described, patients ages 55 to 80 years,
aving previously treated or untreated hypertension and
CG signs of LV hypertrophy (12) were randomized to
nitial therapy with 50 mg/day of losartan or atenolol after
ne to two weeks taking placebo if they had sitting systolic
lood pressure 160 to 200 mm Hg and/or diastolic blood
ressure of 95 to 115 mm Hg. In both groups, hydrochlo-
othiazide was added in case of insufficient pressure lower-
Abbreviations and Acronyms
AF  atrial fibrillation
CI  confidence interval
ECG  electrocardiographic
HF  heart failure
HR  hazard ratio
LV  left ventricular/ventricle
LIFE  Losartan Intervention For Endpoint reduction
in hypertension studyng. Thereafter the study drug was increased to 100 mg/day pnd supplemented with additional antihypertensive therapy
n order to reach target blood pressure of 140/90 mm Hg.
atients were enrolled from June 1995 to May 1997 and
ere followed 4 years (mean 4.8 years) with regular visits.
itting blood pressure was recorded 24 h postdose (range 22
o 26 h).
New-onset AF was identified from annual in-study
CGs that underwent Minnesota coding for AF at a single
CG core center (13). Care of the patients with new-onset
F was left to the discretion of local investigators. After the
topping date in September 2001, patients had a follow-up
linic visit or at least vital status check within six weeks.
aboratory tests were carried out at two laboratories that
ssured comparability of measurements by cross-validation.
Echocardiographic assessment of baseline LV systolic
unction and valvular disease was obtained in approximately
0% of study participants (15,16).
nd points and adjudication. This report in 8,851 pa-
ients (more than 96% of the entire LIFE population) is
ased on analysis of a primary composite end point (n 
93), which is the first occurrence of cardiovascular death,
atal or nonfatal stroke, and fatal or nonfatal myocardial
nfarction. Additional end points included all-cause mortal-
ty (n  735) and the first occurrence of each component of
he composite end point, whether or not preceded by
nother component of the primary end point, including 380
ardiovascular deaths, 485 strokes, and 367 myocardial
nfarctions. All end points were reported by investigators,
ource data verified by independent monitors, and adjudi-
ated by an independent committee on the basis of prespeci-
ed definitions (12). Prevalent coronary, cerebral, or periph-
ral vascular disease and smoking habits were reported by
Figure 1. Trial profile.atients and investigators. Framingham risk score (17) was
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AF in Hypertensive Patients March 1, 2005:712–9stimated from baseline blood pressure, total and high-
ensity lipoprotein cholesterol, smoking, glucose, and ECG
V hypertrophy.
tatistical methods. SPSS version 12.0 (SPSS Inc.,
hicago, Illinois) was used for statistical analysis. Potential
isk factors (including baseline clinical, demographic, and
aboratory data) were assessed for association with new-
nset AF. Cox proportional hazards models were used to
ompare hazard ratios (HRs) between study treatment
llocation groups (losartan or atenolol), and to evaluate
ontributions of differences in the degree of LV hypertrophy
both Cornell voltage-duration product and Sokolow-Lyon
oltage as continuous variables), the Framingham risk score
17), and other covariates. For each baseline characteristic, a
nivariate proportional hazards regression model was used
o estimate the HR and its 95% confidence interval (CI).
ariables without significant effects were eliminated before
eveloping multivariate models. Multivariate analyses were
hen performed using Cox regression models with inclusion
f remaining variables to identify those independently
ssociated with the end points. Two-tailed p  0.05 was
onsidered significant.
ESULTS
atient selection and characteristics. Of 9,193 random-
zed patients, 8,851 patients remained after exclusion of
hose with AF by history or by Minnesota coding of the
aseline ECG (Fig. 1). Rates of new-onset AF in strata
efined by baseline characteristics are given in Table 1,
ichotomized at median values of continuous variables for
isplay purposes.
In the subset of LIFE echocardiography patients without
F by history or at baseline (n  911), there were no
ifferences in prevalences of aortic or mitral valve disease
data not shown), LV ejection fraction (61  9% vs. 61 
%, p 0.889) or left atrial size (3.9 0.6 cm vs. 3.9 0.6
m, p  0.752) between losartan- and atenolol-treated
atients, respectively.
Patients treated with losartan had, compared to those
eceiving atenolol, similar baseline characteristics (Table 2)
nd reductions of systolic (28.5  18.9 mm Hg vs. 27.3
19.3 mm Hg), mean arterial (20.0  11.5 vs. 19.7 
1.5), and diastolic (15.8  10.1 mm Hg vs.  15.9 
0.0 mm Hg) blood pressure, but had more reduction in
CG LV hypertrophy by Cornell voltage-duration product
268  820 mV·ms vs. 122  872 mV·ms, p  0.0001).
There were no differences at baseline or during the study
n concomitant treatment with class IA-IC or III antiar-
hythmic drugs, digoxin, or non-dihydropyridine calcium
hannel blockers between losartan- and atenolol-treated
atients (data not shown). However, atenolol-treated pa-
ients were more likely to receive anticoagulation therapy
5.3% vs. 7.7%, p  0.001).
ew-onset AF. New-onset AF occurred in 150 losartan-6.8 per 1,000 person-years of follow-up) and 221 atenolol- preated patients (10.1 per 1,000 person-years of follow-up,
R  0.67, 95% CI 0.55 to 0.83, p  0.001). Adjustment
or differences in LV hypertrophy by Cornell voltage dura-
ion and Sokolow-Lyon criteria and Framingham risk score
ad only minimal effect on the reduction of new-onset AF
ssociated with losartan (Fig. 2). Furthermore, patients
aking losartan tended to stay in sinus rhythm longer from
aseline (1,809  225 vs. 1,709  254 days from baseline,
 0.057) than those taking atenolol.
ew-onset AF and outcome. Cardiovascular morbidity
nd mortality was more frequent in patients with new-onset
F than with persistent sinus rhythm (Table 3). Patients
ith new-onset AF had an approximately twofold increased
isk of cardiovascular events, about threefold higher risk of
atal or nonfatal stroke, and fivefold increased rate of
ospitalization for heart failure (HF), even after adjustment
or covariates.
Although patients with new-onset AF treated with lo-
artan versus atenolol had similar baseline characteristics
Table 2), losartan-treated patients with new-onset AF had
40% lower rate of subsequent composite events compared
ith atenolol-treated patients (n  31 vs. 51, HR  0.60,
5% CI 0.38 to 0.94, p  0.03). There were substantially
ewer subsequent strokes (n  19 vs. 38, HR  0.49, 95%
I 0.29 to 0.86, p 0.01), a trend toward fewer myocardial
nfarctions (n  9 vs.16, HR  0.60, 95% CI 0.25 to 1.27,
 0.16) and no difference in cardiovascular mortality (n
4 vs. 14, pNS) in losartan- and atenolol-treated patients
ith new-onset AF. In contrast, atenolol-treated patients
ith new-onset AF had fewer hospitalizations for HF (n 
0 vs. 30, HR 0.43, 95% CI 0.25 to 0.76, p 0.004) and
trend toward fewer sudden cardiac deaths (n 2 vs. 6, HR
0.22, 95% CI 0.05 to 1.10, p  0.07).
In multivariate analysis that adjusted for differences in
ge; blood pressure; Framingham risk score; ECG LV
ypertrophy; albuminuria; diabetes; and coronary, cerebral,
nd peripheral vascular disease, both new-onset AF (HR 
.31, 95% CI 1.70 to 3.14, p  0.001) and atenolol
reatment (HR  1.27, 95% CI 1.05 to 1.54, p  0.015)
ere independently associated with fatal and nonfatal stroke
mong patients free of AF at baseline.
rediction of new-onset AF. For each baseline character-
stic, a univariate proportional hazards regression model was
sed to estimate the hazard ratio for new-onset AF and its
5% CI (Table 4). Variables with significant associations (p
0.05) were used to develop multivariate models. To
dentify the most important factors associated with devel-
pment of new-onset AF, we developed four multivariate
rediction models (Table 5). In the first model, which
onsidered baseline characteristics, age was by far the most
mportant predictor of new-onset AF, with each year of age
ssociated with a 9% higher rate of new-onset AF. Age is
ollowed, in order, by male gender (56% increase in risk
ompared to women), systolic blood pressure (6% increase
er 10 mm Hg) and ECG LV hypertrophy by Cornell
roduct (4% increase per 100 mV·ms). In an alternative
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March 1, 2005:712–9 AF in Hypertensive Patientsable 1. New-Onset Atrial Fibrillation in Relation to Baseline Characteristics
New-Onset Atrial Fibrillation, n (%)
Losartan-Treated p Atenolol-Treated p All p
ge
65 yrs 33 (1.9) 37 (2.2) 70 (2.0)
65 yrs 117 (4.3) 0.001 184 (6.8) 0.001 301 (5.5) 0.001
ender
Male 75 (3.7) 115 (5.7) 190 (4.7)
Female 75 (3.1) 0.263 106 (4.4) 0.051 181 (3.8) 0.026
ace
Caucasian 143 (3.5) 217 (5.3) 360 (4.4)
Black 5 (1.9) 0.216 2 (0.8) 0.000 7 (1.3) 0.001
ody-mass index
27.5 kg/m2 68 (3.1) 111 (5.0) 179 (4.0)
27.5 kg/m2 82 (3.7) 0.231 106 (5.0) 0.936 188 (4.4) 0.434
ystolic blood pressure
175 mm Hg 59 (2.6) 92 (4.1) 151 (3.3)
175 mm Hg 91 (4.3) 0.001 129 (6.0) 0.005 220 (5.1) 0.000
iastolic blood pressure
98 mm Hg 70 (3.4) 114 (5.5) 184 (4.5)
98 mm Hg 80 (3.3) 0.855 107 (4.6) 0.148 187 (4.0) 0.205
eart rate
72 beats/min 52 (3.0) 105 (5.7) 157 (4.4)
72 beats/min 98 (3.7) 0.188 114 (4.5) 0.070 212 (4.1) 0.521
ornell voltage-duration criteria
2,668 mV·ms 49 (2.3) 93 (4.3) 142 (3.3)
2,668 mV·ms 101 (4.4) 0.001 128 (5.7) 0.032 229 (5.0) 0.001
okolow-Lyon criteria
29 mV 77 (3.5) 107 (5.0) 184 (4.2)
29 mV 73 (3.2) 0.589 114 (5.1) 0.899 187 (4.1) 0.815
ramingham risk score
21% 64 (2.8) 94 (4.2) 158 (3.5)
21% 86 (3.9) 0.044 127 (5.8) 0.017 213 (4.9) 0.002
iabetes
No 125 (3.2) 195 (5.1) 320 (4.1)
Yes 25 (4.5) 0.129 26 (4.6) 0.756 51 (4.6) 0.478
oronary artery disease
No 123 (3.2) 192 (5.0) 315 (4.1)
Yes 27 (4.3) 0.152 29 (5.4) 0.674 56 (4.8) 0.255
erebral vascular disease
No 137 (3.3) 203 (5.0) 340 (4.2)
Yes 13 (3.7) 0.644 18 (5.5) 0.694 31 (4.6) 0.618
eripheral vascular disease
No 139 (3.3) 211 (5.0) 350 (4.2)
Yes 11 (4.2) 0.477 10 (4.6) 0.874 21 (4.4) 0.815
otassium
4.1 mmol/l 59 (3.7) 90 (5.7) 149 (4.7)
4.1 mmol/l 82 (3.2) 0.429 109 (4.3) 0.036 191 (3.8) 0.037
otal cholesterol
6.0 mmol/l 71 (3.4) 102 (5.1) 173 (4.2)
6.0 mmol/l 70 (3.3) 0.809 97 (4.6) 0.524 167 (4.0) 0.527
DL cholesterol
1.44 mmol/l 61 (2.9) 96 (4.7) 157 (3.8)
1.44 mmol/l 80 (3.8) 0.124 103 (5.0) 0.666 183 (4.4) 0.187
lucose
5.4 mmol/l 69 (3.3) 104 (4.9) 173 (4.1)
5.4 mmol/l 75 (3.6) 0.536 98 (4.8) 0.794 173 (4.2) 0.843
reatinine
83 mol/l 71 (3.4) 112 (5.1) 183 (4.3)
83 mol/l 73 (3.4) 1.000 90 (4.5) 0.311 163 (3.9) 0.391
rine albumin/creatinine ratio
1.25 mg/mmol 53 (2.6) 81 (4.2) 134 (3.4)
1.25 mg/mmol 81 (4.1) 0.010 109 (5.5) 0.059 190 (4.8) 0.002DL  high-density lipoprotein.
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AF in Hypertensive Patients March 1, 2005:712–9odel (data not shown) lower ECG LV hypertrophy by
ornell product at the annual re-examination was predictive
f less new-onset AF.
Addition of study treatment to the second model (Table
) indicated that randomization to losartan was associated
ith a 33% lower rate of new-onset AF, independent of
ther risk factors (p  0.001). Addition of study treatment
o the model left the other predictors of new-onset AF from
he first model almost unchanged, documenting an inde-
endent effect of losartan treatment on prevention of AF.
dditional models showed that age and male gender pre-
icted new-onset AF within each treatment group consid-
red separately.
ISCUSSION
his study is, to our knowledge, the first to show that one
ntihypertensive treatment regimen is more effective than
igure 2. Kaplan-Meier curves illustrating new-onset electrocardiogram-
Table 2. Baseline Demographic and Clinical C
Fibrillation Randomized to Losartan or Ateno
Characteristic
Age (yrs)
Female gender (%)
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
Heart rate (beats/min)
Body mass index (kg/m2)
Cornell voltage-duration (mV·ms)
Sokolow-Lyon (mV)
Framingham risk (%)
Medical history
Diabetes mellitus (%)
Coronary disease (%)
Cerebrovascular disease (%)
Peripheral vascular disease (%)
Laboratory values
Serum-potassium (mmol/l)
Total cholesterol (mmol/l)
HDL cholesterol (mmol/l)
Glucose (mmol/l)
Creatinine (mol/l)
Urine albumin/creatinine (mg/mmol)
HDL  high-density lipoprotein; NS  not significant.s
erified atrial fibrillation during follow-up. CI  confidence interval; HR
hazard ratio.nother with equal blood pressure reduction in reducing
ew-onset AF. That losartan reduced the rate of new-onset
F by 33% compared to atenolol with similar blood
ressure reduction is surprising, as many regard beta-
lockade a first-line therapy to prevent AF as well as
referred treatment for rate-control in established AF (10).
n addition, patients receiving losartan-based therapy
ended to stay in sinus rhythm longer.
Furthermore, our study demonstrates the clinical rele-
ance of preventing new-onset AF, as it was associated with
wo-, three-, and five-fold higher rates of cardiovascular
orbidity and mortality, stroke, or hospitalization for HF.
ew-onset AF was associated with increased cardiovascular
orbidity and mortality even when taking additional risk
actors, as summarized by the Framingham risk score and
CG measures of LV hypertrophy, into account. Further-
ore, we found losartan-based treatment significantly re-
uced cardiovascular events in patients with new-onset AF,
ith the difference of 19 strokes between the treatment-
rms in patients with new-onset AF, comprising about 25%
f the 77 fewer strokes associated with losartan- versus
tenolol-based therapy in the entire LIFE study (12).
owever, patients with new-onset AF had fewer hospital-
zations for HF when treated with atenolol than losartan.
his might be explained by the fact that atenolol showed a
etter effect on LV ejection fraction in the LIFE echocar-
iographic substudy, associated with greater reduction in
eart rate (18). Of further interest was the trend toward a
ower risk of sudden cardiac death associated with new-
nset AF in atenolol- than in losartan-treated patients. This
s in contrast to findings in the LIFE trial’s diabetic
cteristics of Patients With New-Onset Atrial
artan
150)
Atenolol
(n  221) p
 6.9 70.7  6 NS
(50) 106 (48) NS
 14.2 177.8  13.5 NS
 8.8 96.5  8.4 NS
 11.4 72.4  11.6 NS
 5.6 28  4.6 NS
 993 2,975  929 NS
 11.5 30.8  10.9 NS
 9.5 24.2  9.4 NS
6.7 11.8 NS
8.0 13.1 NS
8.7 8.1 NS
7.3 4.5 NS
NS
 0.4 4.1  0.4 NS
 1.3 5.9  1.0 NS
 0.4 1.5  0.5 NS
 2.1 6.1  2.0 NS
 31 84.8  16.6 NS
 53.6 6.8  16.1 0.05hara
lol
Los
(n 
70.3
75
177.3
97.9
74.3
28.8
2,990
30
23.7
1
1
4.1
6
1.5
6.1
88.9
16.2ubpopulation (19) and merits further research.
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March 1, 2005:712–9 AF in Hypertensive PatientsOur study extends previous reports suggesting that renin-
ngiotensin system blockade by either angiotensin-
onverting enzyme inhibition (4,20) or angiotensin II re-
eptor blockade (9) reduces incident AF. In the TRACE
tudy new-onset AF was reduced by 45% with trandolapril
4). A subanalysis of the SOLVD study reported that
ew-onset AF was reduced as much as 78% with enalapril
20). However, both studies were placebo-controlled, and
herefore superior antihypertensive effect of the study drug
ay have contributed to the lower rate of AF. Our study
urther supports this inference, as higher systolic blood
ressure was an independent predictor of new-onset AF,
nderlining the importance of blood pressure control for
revention of AF.
Furthermore, the present results are consistent with our
revious finding that LIFE patients with a history of AF
enefited from losartan-based treatment, with 42% reduc-
ion of both composite end points and cardiovascular
ortality and 45% risk reduction for stroke (11).
able 3. End Points in Patients With and Without New-onset A
End Point
New-Onset Atrial
Fibrillation*
(n  371)
Sinus R
(n  8
Rate† n (%) Rate‡ n
rimary composite end point 47.4 82 22.1 22.5 9
omponents
Cardiovascular mortality 15.2 28 7.5 8.4 3
Stroke 32.0 57 15.4 10.3 4
Myocardial infarction 13.5 25 6.7 8.2 3
ther end points
Total mortality 21.8 40 10.8 16.8 6
Hospitalization for
Angina pectoris 6.5 12 3.2 5.6 2
Heart failure 27.0 50 13.5 5.1 2
Revascularization 7.5 14 3.8 4.5 1
Sudden cardiac death‡ 4.3 8 2.2 3.7 1
Composed of resuscitated cardiac arrest, cardiac death within 24 h; †for degree of
atient-years of follow-up.
CI  confidence interval.
able 4. Univariate Predictors of New-Onset Atrial Fibrillation
Variable
Hazard Ratio
(95% CI)
p
Value
ge (yrs) 1.09 (1.07–1.10) 0.001
ale gender 1.3 (1.06–1.60) 0.011
ystolic blood pressure (mm Hg) 1.02 (1.01–1.02) 0.001
iastolic blood pressure (mm Hg) 0.99 (0.98–1.00) 0.046
ornell voltage-duration
(mV·ms/100)
1.013 (1.004–1.022) 0.006
okolow-Lyon voltage (mV) 1.01 (0.997–1.02) 0.170
ramingham risk score (%) 1.02 (1.01–1.03) 0.001
oronary disease (yes/no) 1.28 (0.99–1.67) 0.062
otal cholesterol (mmol/l) 0.89 (0.80–0.98) 0.014
otassium (mmol/l) 0.78 (0.58–1.04) 0.091
og UACR (mg/mmol) 1.44 (1.23–1.67) 0.001
reatment with losartan 0.67 (0.54–0.82) 0.001
eart rate, body mass index, diabetes, cerebral and peripheral vascular disease,
igh-density lipoprotein cholesterol, plasma glucose, and creatinine were not signif-cant predictors (p  0.20).
CI  confidence interval; UACR  urine albumin/creatinine ratio.echanisms. One explanation for the added benefit of
osartan in preventing new-onset AF and events associated
herewith in hypertensive patients with LV hypertrophy
ould be parallel effects of losartan on regression of atrial
nd ventricular hypertrophy. Our data suggest that sus-
ained LV hypertrophy is an important predictor of new-
nset AF. We have recently shown in the LIFE echocar-
iography substudy (21) that patients with LV hypertrophy
lso exhibit increased left atrial size, which has been
ssociated with increased stroke risk in normotensive (22)
nd hypertensive adults (23). The greater regression of
CG and echo LV hypertrophy with losartan- than
tenolol-based therapy (24,25) may have been paralleled by
reater reduction of left atrial overload and dilatation,
hereby reducing stimuli to new-onset AF. A recent animal
tudy showed that angiotensin II receptor blockade pre-
ented the promotion of AF by reducing atrial structural
emodeling (5). Furthermore, a recent study suggests that
enin-angiotensin system polymorphisms are associated
ith non-familial AF (26).
tudy limitations. Potential limitations of the study in-
lude the evaluation of an overwhelmingly Caucasian pop-
lation from the Nordic countries, the United Kingdom,
nd the U.S. All patients had ECG LV hypertrophy and
ypertension and were thus at high cardiovascular risk. On
he other hand, our annual ECG sampling undoubtedly
nderestimated the incidence of AF and reduced precision
f treatment effect estimates.
Although the analysis of AF was not prespecified in the
995 LIFE study analysis plan, evaluation of treatment
ffects in the subgroup of patients with new-onset AF was
planned secondary analysis before study termination
September 2001) and unblinding. Furthermore, patients
ith new-onset AF were recruited for hypertension and
CG LV hypertrophy and randomization within patients
ith new-onset AF may not be balanced.
Fibrillation
Adjusted
Hazard Ratio*
(95% CI)
p
Value
Unadjusted
Hazard Ratio
(95% CI)
p
Value(%)
10.7 1.88 (1.50–2.36) 0.001 2.12 (1.70–2.66) 0.001
4.2 1.57 (1.07–2.31) 0.021 1.80 (1.22–2.64) 0.003
5.0 2.82 (2.14–3.72) 0.000 3.12 (2.37–4.12) 0.001
4.0 1.49 (0.99–2.24) 0.055 1.65 (1.10–2.47) 0.016
8.2 1.15 (0.84–1.59) 0.377 1.29 (0.94–1.78) 0.113
2.8 1.04 (0.58–1.86) 0.895 1.15 (0.65–2.06) 0.627
2.5 4.96 (3.64–6.74) 0.001 5.55 (4.08–7.55) 0.001
2.3 1.47 (0.85–2.53) 0.167 1.66 (0.97–2.86) 0.066
1.8 1.01 (0.50–2.05) 0.981 1.15 (0.57–2.35) 0.692
ntricular hypertrophy, Framingham risk score and treatment allocation; ‡per 1,000trial
hythm
,480)
11
52
28
42
95
35
15
91
56
left veBecause outcomes were analyzed by the intention-to-
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AF in Hypertensive Patients March 1, 2005:712–9reat principle, without restriction after study drug discon-
inuation, open-label use of angiotensin II receptor blocker/
ngiotensin-converting enzyme inhibitor/beta-blocker may
ave diminished differences between the groups. However,
e found no statistical differences in open-label drug usage
etween losartan versus atenolol arms in patients with
ew-onset AF. Furthermore, information is unavailable
egarding levels of anticoagulation between treatment arms.
onclusions. Our novel finding is that new-onset AF and
ubsequent stroke were significantly reduced by losartan-
ompared with atenolol-based antihypertensive treatment
ith similar blood pressure reduction. Approximately 25%
f the total reduction in stroke associated with losartan- as
pposed to atenolol-based antihypertensive treatment in the
ntire LIFE study occurred in the subset of patients with
ew-onset AF.
cknowledgment
e are indebted to Sigrid Helle Berg for her dedicated
ork with the LIFE study.
eprint requests and correspondence: Dr. Kristian Wachtell,
igshospitalet, Department of Medicine B2142, 9 Blegdamsvej,
K-2100 Copenhagen, Denmark. E-mail: kristian@wachtell.net.
EFERENCES
1. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based
study of the long-term risks associated with atrial fibrillation: 20-year
follow-up of the Renfrew/Paisley study. Am J Med 2002;113:359–64.
2. Vidaillet H, Granada JF, Chyou PH, et al. A population-based study
of mortality among patients with atrial fibrillation or flutter. Am J Med
2002;113:365–70.
3. Tsang TS, Petty GW, Barnes ME, et al. The prevalence of atrial
fibrillation in incident stroke cases and matched population controls in
Rochester, Minnesota: changes over three decades. J Am Coll Cardiol
2003;42:93–100.
Table 5. Multivariate Predictors of New-Onse
Variable Ch
Model 1: all patients
Age (yrs)
Male gender
Systolic blood pressure (10 mm Hg)
Cornell voltage-duration (mV·ms/100)
Model 2: all patients with treatment
allocation as a covariate
Age (yrs)
Male gender
Systolic blood pressure (10 mm Hg)
Cornell voltage-duration (mV·ms/100)
Randomization to losartan
Model 3: patients treated with losartan
Age (yrs)
Male gender
Model 4: patients treated with atenolol
Age (yrs)
Male gender
CI  confidence interval.4. Pedersen OD, Bagger H, Køber L, Torp-Pedersen C. Trandolapril
reduces the incidence of atrial fibrillation after acute myocardialinfarction in patients with left ventricular dysfunction. Circulation
1999;100:376–80.
5. Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin II
type 1 receptor antagonist on electrical and structural remodeling in
atrial fibrillation. J Am Coll Cardiol 2003;41:2197–204.
6. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting
enzyme inhibition on the development of the atrial fibrillation sub-
strate in dogs with ventricular tachypacing-induced congestive heart
failure. Circulation 2001;104:2608–14.
7. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling
and atrial fibrillation in experimental congestive heart failure. Cardio-
vasc Res 2002;54:456–61.
8. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist
prevents electrical remodeling in atrial fibrillation. Circulation 2000;
101:2612–7.
9. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to
maintain sinus rhythm in patients with long-lasting persistent atrial
fibrillation: a prospective and randomized study. Circulation 2002;106:
331–6.
0. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines
for the management of patients with atrial fibrillation: executive
summary. A report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines and the Euro-
pean Society of Cardiology Committee for Practice Guidelines and
Policy Conferences (Committee to Develop Guidelines for the Man-
agement of Patients With Atrial Fibrillation): developed in collabo-
ration with the North American Society of Pacing and Electrophysi-
ology. J Am Coll Cardiol 2001;38:1231–66.
1. Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity
and mortality in hypertensive patients with a history of atrial fibrilla-
tion: the Losartan Intervention for End Point Reduction in Hyper-
tension (LIFE) study. J Am Coll Cardiol 2005;45:705–12.
2. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity
and mortality in the Losartan Intervention For Endpoint reduction in
hypertension study (LIFE): a randomised trial against atenolol. Lancet
2002;359:995–1003.
3. Dahlöf B, Devereux RB, de Faire U, et al. The Losartan Intervention
For Endpoint reduction (LIFE) in Hypertension Study. Am J Hyper-
tens 1997;10:705–13.
4. Dahlöf B, Devereux RB, Julius S, et al. Characteristics of 9194 patients
with left ventricular hypertrophy: the LIFE study. Hypertension
1998;32:989–97.
5. Wachtell K, Bella JN, Liebson PR, et al. Impact of different partition
values on prevalences of left ventricular hypertrophy and concentric
geometry in a large hypertensive population: the LIFE study. Hyper-
ial Fibrillation
are Hazard Ratio (95% CI) p
1.09 (1.07–1.10) 0.001
1.56 (1.27–1.92) 0.001
1.09 (1.01–1.18) 0.019
1.01 (1.00–1.02) 0.035
1.09 (1.07–1.11) 0.001
1.56 (1.27–1.92) 0.001
1.09 (1.01–1.18) 0.023
1.01 (1.001–1.02) 0.030
0.67 (0.54–0.82) 0.001
1.08 (1.06–1.11) 0.001
1.45 (1.05–2.00) 0.025
1.10 (1.08–1.12) 0.001
1.55 (1.19–2.03) 0.001t Atr
i-Squ
105.5
18.0
5.5
4.1
106.2
17.7
5.2
4.3
15.1
42.0
5.0
83.2
10.5tension 2000;35:6–12.
11
1
1
2
2
2
2
2
2
2
719JACC Vol. 45, No. 5, 2005 Wachtell et al.
March 1, 2005:712–9 AF in Hypertensive Patients6. Devereux RB, Bella JN, Boman K, et al. Echocardiographic left
ventricular geometry in hypertensive patients with electrocardiographic
left ventricular hypertrophy: the LIFE study. Blood Press 2001;
10:74–82.
7. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated
coronary risk profile. A statement for health professionals. Circulation
1991;83:356–62.
8. Wachtell K, Gerdts E, Palmieri V, et al. Systolic left ventricular
function improves more by beta-blockade than losartan: the LIFE
study (abstr). Am J Hypertens 2003;16:181A.
9. Lindholm LH, Dahlöf B, Edelman J, et al. Effects on losartan on
sudden cardiac death in people with diabetes: data from the LIFE
study. Lancet 2003;362:619–20.
0. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decrease the
incidence of atrial fibrillation in patients with left ventricular dysfunc-
tion. Insight from the Studies Of Left Ventricular Dysfunction
(SOLVD) Trials. Circulation 2003;107:2926–31.
1. Gerdts E, Oikarinen L, Palmieri V, et al. Correlates of left atrial size
in hypertensive patients with left ventricular hypertrophy: the LosartanIntervention For Endpoint Reduction in Hypertension (LIFE) study.
Hypertension 2002;39:739–43.
2. Benjamin EJ, D’Agostino RB, Belanger AJ, Wolf PA, Levy D. Left
atrial size and the risk of stroke and death. The Framingham Heart
Study. Circulation 1995;92:835–41.
3. Gottdiener JS, Reda DJ, Williams DW, et al. Effect of single-drug
therapy on reduction of left atrial size in mild to moderate hyperten-
sion: comparison of six antihypertensive agents. Circulation 1998;98:
140–8.
4. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardio-
graphic left ventricular hypertrophy by losartan versus atenolol: the
Losartan Intervention for Endpoint reduction in Hypertension (LIFE)
study. Circulation 2003;108:684–90.
5. Devereux RB, Dahlöf B, Gerdts E, et al. Regression of hypertensive
left ventricular hypertrophy by losartan compared with atenolol. The
Losartan Intervention for Endpoint Reduction in Hypertension
(LIFE) trial. Circulation 2004;110:1456–62.
6. Tsai CT, Lai LP, Lin JL, et al. Renin-angiotensin system
gene polymorphisms and atrial fibrillation. Circulation 2004;109:
1640 – 6.
